ArticleMolecular cancer therapeutics2025

Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency.

Antoine Simoneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.